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Abstract: The aim of the current study was to compare changes in serum biomarkers, including
inflammatory mediators, signaling molecules, growth factors and markers of bone turnover after a
single intravenous infusion of 5 mg zoledronic acid (ZA, a long-acting bisphosphonate; n = 20) or
placebo (n = 20) among patients with Modic changes (MC) and chronic low back pain in a randomized
controlled design. The MCs were classified into M1, predominating M1, predominating M2, and M2.
We measured the serum concentrations of 39 biomarkers at baseline, and one month and one year
after treatment. After Benjamini–Hochberg (B–H) correction, we observed significant differences in
three biomarkers over one year: Interferon-γ-inducible protein (IP-10) had risen in the ZA group
(p = 0.005), whereas alkaline phosphatase (AFOS) and intact procollagen I N-terminal propeptide
(iPINP) had significantly decreased in the ZA group, but had not changed in the placebo group
(p < 0.001 for both). Change in iPINP correlated with change in the volume of all MC and M1 lesions.
ZA downregulated bone turnover markers as expected and, surprisingly, increased the chemokine
IP-10 relative to placebo treatment. This adds to our knowledge of the effects of ZA on MC and the
biomarkers that signal this process.
Keywords: serum biomarkers; magnetic resonance imaging; Modic change; randomized trial;
zoledronic acid; chronic low back pain
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1. Introduction
A Modic change (MC) is a vertebral bone marrow change visible in magnetic resonance imaging
(MRI). Three different types of MC have been described, of which Type 1 (M1) shows fibrovascular
replacement of the bone marrow and represents an inflammatory lesion; Type 2 MC (M2) shows
fatty replacement of the red bone marrow; and Type 3 MC (M3) demonstrates subchondral bone
sclerosis [1–4]. MC is associated with chronic low back pain (CLBP) [5–7] and M1 shows a stronger
association with CLBP than other MC types [8–10]. In a Finnish patient study, conversion from M1 to
M2 over two years was associated with improvement of pain symptoms [11]. Similar findings have
been obtained among Danish patients [12].
Both infectious or autoimmune etiologies have been suggested as causes of MC, and both
presuppose structural damage of the endplate [13–15]. However, improved diagnostic tools are needed
to detect early MC lesions. One novel pre-clinical technique that holds great clinical potential is nuclear
magnetic resonance spectroscopy, which is a noninvasive method to quantify Cutibacterium (formerly
Propionibacterium) acnes load on the intervertebral discs [16,17]. There is also an urgent need to
develop other MC biomarkers in order to increase early diagnosis and the choice of the right treatment
and establishment of MC prognosis [13].
A biomarker is defined as a characteristic that is objectively measured and evaluated as an
indicator of normal biologic or pathogenic processes, or pharmacologic responses to a therapeutic
intervention [18]. Molecular diagnostic techniques have developed in recent years and may be helpful
in revealing diseases at their early stage. However, only two studies of MC serum biomarkers have
been published so far. In the first, serum high-sensitive C-reactive protein (hs-CRP) was higher
among patients with M1 than among those with M2, or those without MC but with CLBP [19].
Another small French case-control study in turn found no difference in bone mineral density and
bone remodeling marker levels (serum C-terminal crosslinked type 1 telopeptide, procollagen type
1 N-terminal propeptide, osteocalcin, and bone-specific alkaline phosphatase) among chronic LBP
patients with M1 or without MC [20]. We have previously demonstrated how a single intravenous
infusion of 5 mg zoledronic acid (ZA) decreased the intensity of pain among patients with CLBP in
the short-term in comparison to placebo [21]. We hypothesized that the beneficial effect of ZA on
symptoms may be partly due to the reduction of inflammation, which in turn may be reflected by
serum biomarkers related to inflammation and bone turnover. Therefore, the objective of our study
was to compare the effect of a single intravenous infusion of 5 mg ZA to that of placebo infusion on the
change in the serum biomarker profile of patients with MC, and to evaluate whether serum biomarkers
correlate with the type and size of MC at baseline.
2. Materials and Methods
2.1. Study Design and Selection of Patients
The study population consisted of patients with CLBP and MC in lumbar MRI [21]. Inclusion
criteria were LBP for at least three months, LBP intensity of at least six on the 10-cm Visual Analog
Scale (VAS) or an Oswestry Disability Index (ODI) [22] of at least 30% and an MC (M1, M2, or M1/2) in
MRI [21].
The Oulu University Hospital ethics committee approved the study protocol (121/2008, 18 August
2008). Informed consent was obtained from all participants (ClinicalTrials.gov NCT01330238).
2.2. Treatment Intervention
Patients were randomized into a ZA group with an infusion of 5 mg of ZA (n = 20) or a placebo
group (saline infusion, n = 20). Before the administration of the infusion, all the patients received 600
mg of ibuprofen or 1 g of paracetamol orally to prevent potential acute phase reactions, and 100,000
units of Vitamin D (VigantolR) orally to avoid hypocalcemia [21].
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2.3. Magnetic Resonance Imaging
The average interval between baseline imaging and infusion was four months (range 0.4 to
11.5 months). Follow-up imaging was performed on average 11.9 months (range 11 to 13 months) after
infusion [23]. The MRI equipment of the baseline imaging included five 1.5 T units (GE Signa Twinspeed,
General Electric Medical Systems, Milwaukee, WI, USA; Philips Achieva and Philips Intera, Philips
Medical Systems, Eindhoven, The Netherlands; Siemens Avanto and Siemens Espree, Siemens Medical,
Erlangen, Germany), a 0.34 T unit (Siemens Magnetom C, Siemens Medical, Erlangen, Germany) and a
0.23 T unit (Philips Panorama, Philips Medical Systems, Eindhoven, The Netherlands). The imaging
sequences were sagittal T1-weighted (T1 W) turbo spin-echo (TSE) or fast spin-echo (FSE) with fluid
attenuation inversion recovery (FLAIR), sagittal T2-weighted (T2 W) TSE/FSE, and short tau inversion
recovery sequences (STIR). The specific imaging parameters have been described previously [23].
The MRI equipment of the one-year follow-up imaging included two 1.5 T units (GE Signa Twinspeed
and GE Optima, General Electric Medical Systems, Milwaukee, WI, USA) and a 3 T unit (Siemens Skyra,
Siemens Medical, Erlangen, Germany). Imaging protocols were established for clinical spine imaging.
2.4. Image Analysis
We analyzed the MRIs for type and volume of each MC from sagittal images at a clinical
workstation (Neaview Radiology, version 2.23, Neagen Corporation, Oulu, Finland) [23]. MC type
was assessed using T1 W and T2 W images as previously described [10]. Four MC type groups were
created: M1 (100%), predominating M1 (M1/2 (65:35%)), predominating M2 (M1/2 (35:65%)) and
M2 (100%). The first two groups were considered M1-dominant, and the latter two M2-dominant.
M1 was defined as consisting of purely oedemic signal changes and M2 consisting of purely fatty signal
changes. Predominating M1 was defined as mixed Type 1/2 MC with more oedemic signal changes and
predominating M2 as Type 1/2 MC with more fatty signal changes. The MC area (cm2) was determined
from T2 W images. The volume (cm3) of each MC lesion was calculated by multiplying the area with
the spacing.
2.5. Analysis of Serum Biomarkers
Whole blood was drawn at noon from fasting patients using serum collection tubes prior to
the intervention (baseline), at one-month and at one-year follow-up. We told all the participants
not to exercise, eat, or drink the previous evening or the morning before the blood were to be taken.
The blood samples were allowed to clot at room temperature for 30–60 min and then centrifuged at
2500× g for 10 min at 4 ◦C. The resulting serum supernatant was stored in aliquots, first at −20 ◦C,
and were then transferred within 2–20 h to −70 ◦C. We took serum samples from 40 patients at three
timepoints (n = 120) to assess the selected inflammatory and signaling molecules, growth factors and
markers of bone turnover. We measured the serum concentrations of 50 biomarkers, and quantified
38 biomarkers using electro-chemiluminescent based multi-array immunoassays from MesoScale
Discovery (MSD, Rockville, MD, USA), following the protocol of the manufacturer: Chemokine panel:
Eotaxin, eotaxin-3, interferon-gamma-inducible protein (IP)-10, macrophage inflammatory protein
(MIP)-1-alpha, MIP-1-beta, monocyte chemotactic protein (MCP)-1, MCP-4, macrophage-derived
chemokine (MDC)-1, regulated on activation normal T-expressed and secreted (RANTES), thymus and
activation regulated chemokine (TARC); Cytokine panel: Granulocyte–macrophage colony stimulating
factor (GM-CSF), interleukin (IL)-5, interleukin (IL)-7, IL-12/23p40, IL-15, IL-16, IL-17A, tumor necrosis
factor (TNF)-beta; Inflammation panel: Interferon (IFN)-gamma, IL-1-alpha, IL-1-beta, IL-2, IL-6,
IL-8, IL-12p70, TNF-alpha, IL-4, IL-10, IL-13; Angiogenesis panel: Vascular endothelial growth factor
(VEGF)-A, VEGF-C, VEGF-D, TEK receptor tyrosine kinase (Tie-2), fms related tyrosine kinase 1 (Flt-1),
basic fibroblast growth factor (bFGF); and Vascular injury panel: Intercellular adhesion molecule
(ICAM)-1, vascular cell adhesion molecule (VCAM)-1, serum amyloid A (SAA). To analyze the
interleukin 1 receptor antagonist (IL-1RA), we used epidermal growth factor (EGF), hepatocyte growth
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factor (HGF), interferon-alpha (IFN-A), interleukin-2 receptor (IL-2R) and monokine induced by
gamma-interferon (MIG-1), a Cytokine Human Magnetic Multi-Plex Panel (Thermo Fisher Scientific,
Waltham, MA, USA), according to the manufacturer’s instructions. The receptor activator of NF-κB
ligand (RANKL) was measured using a commercial Luminex single plex kit (Human RANKL single
plex kit, MilliplexTM Map, Merck Millipore, Billerica, MA, USA), and soluble interleukin-1 receptor,
type II (IL-1sRII) with a human IL-1RII Quantikine Elisa kit (R&D Systems, Minneapolis, MN, USA).
All Luminex assays were performed using Luminex xMAP Technology (Bio-Plex 200 System; BioRad,
Hercules, CA, USA). For the IL-1sRII Elisa assay, absorption was read at 450 nm using an ELISA plate
absorbance reader, and the correction was made at 570 nm (Multiskan MS, Thermo Scientific, Vantaa,
Finland). Plasma alkaline phosphatase activity (AFOS) was analyzed using the IFCC recommended
enzymatic method (Advia, Siemens, Germany). Serum highly sensitive CRP (hs-CRP) was analyzed
using a nephelometric instrument (BN ProSpec, Siemens, Germany). Intact procollagen I N-terminal
propeptide (iPINP) and C telopeptide of type I collagen (CTX-I) analyses were performed using the
IDS-iSYS Multi-Discipline Automated System (IDS, Bolton, UK). As the results of 11 biomarkers
(EGF, GM-CSF, IL-1A, IL-1B, IL-1RA, IL-2, IL-4, IL-5, IL-10, IL-12p70, IL-13) were below the limit
of quantification for more than half of the samples in the whole study, we excluded them from the
final results.
2.6. Statistical Analyses
The background variables are presented as frequencies with proportions and means with standard
deviations. We compared these variables of the ZA and placebo groups using the chi-square test or
independent samples t-test, respectively. The serum biomarkers at baseline, one month and one year are
separately presented as medians with interquartile range for the ZA and placebo groups. The change
in serum biomarkers from baseline to one month and one year in the ZA and placebo groups, and in
the M1- and M2-dominant MC were compared using Mann–Whitney’s U-test. The change in the serum
biomarkers from baseline to one month and one year in the ZA and placebo groups, and in the M1- and
M2-dominant MC were compared separately, using the Wilcoxon signed-rank test. We analyzed the
correlation of the change in serum biomarkers from baseline to one year with a change in primary MC
total volume, M1 volume and M2 volume, and with a change in LBP using Spearman’s rank correlation
coefficient. The Benjamini–Hochberg (B–H) procedure, with a 10% false discovery rate, was used to
correct for multiple comparisons. We used IBM SPSS Statistics, version 24.0 to conduct the analyses.
3. Results
3.1. Study Population
All 40 enrolled, eligible patients participated in the one-year follow-up. There were no statistically
significant differences between the baseline demographic characteristics of the ZA and placebo groups
(Table 1). The patients’ mean age was 50 (SD 8.3) and mean body mass index (BMI) 26.8 (SD 3.2).
The median duration of LBP was 330 (IQR 216-365) days and the mean VAS score for LBP was 6.7 (SD 1.5).
The baseline serum biomarker concentrations of the placebo and ZA groups did not differ significantly.
The results of 11 biomarkers were below the limit of quantification for more than half of the
samples in the whole study and were thus excluded from the final results. Table 2 presents the results
of all the 39 serum biomarkers analyzed. The significant changes are in bold in Table 2 and the markers
that remained significant after B–H correction are marked with an asterisk. At one-month follow-up,
IL-8 in the placebo group and intact procollagen I N-terminal propeptide (iPINP) in the ZA group
had decreased, whereas IP-10, MCP-1, SAA, and hs-CRP had increased in the ZA group (Table 2,
Figures S1–S4). Compared to placebo, the decrease in biomarker concentration from baseline to one
month was greater in the ZA group in terms of iPINP (median of change −9.3 vs. −0.7 ng/mL, p = 0.018)
and in CTX-1 (−0.27 vs. −0.02 pg/mL, p = 0.009). At one month, there were no significant differences
between the ZA and placebo groups after B–H correction.
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Table 1. Characteristics of patients treated with zoledronic acid (ZA) and placebo. Group differences
between age, body mass index (BMI), and Modic changes (MC) volumes were analyzed using the t-test.
Otherwise, the chi-square test was used.
Variable ZA Placebo p-Value
Age (years), mean (SD) 49.2 (9.3) 51.5 (7.3) 0.400
BMI (kg/m2), mean (SD) 26.1 (3.3) 27.4 (3.2) 0.203
Males, n (%) 15 (75.0%) 11 (55.0%) 0.320
Regular smoker, n (%) 5 (25.0%) 6 (30.0%) >0.999
Primary MC type, n (%) 0.103
MI 3 (15.0%) 3 (15.0%)
MI/II-1 14 (70.0%) 7 (35.0%)
MI/II-2 2 (10.0%) 8 (40.0%)
MII 1 (5.0%) 2 (10.0%)
Number of MCs, n (%) 0.333
1 10 (50.0%) 14 (70.0%)
2 or more 10 (50%) 6 (30.0%)
Volume of primary MC, mean (SD)
Type 1 7443 (4474) 5044 (3551) 0.068
Type 2 4542 (3897) 5868 (4840) 0.346
Total 11,985 (5140) 10,911 (5963) 0.546
Osteoarthritis, n (%) 1 (5.0%) 6 (30.0%) 0.091
Back pain (VAS), mean (SD) 6.6 (1.4) 6.8 (1.6) 0.646
Leg pain (VAS), mean (SD) 3.0 (3.1) 2.9 (2.3) 0.864
Oswestry disability index, mean (SD) 30.1 (11.0) 34.9 (9.8) 0.157
Table 2. Median concentrations and interquartile range (IQR) of serum biomarkers at baseline,
one month and one year according to intervention (zoledronic acid (ZA) or placebo infusion). P1 shows
the significance of the change in each respective biomarker concentration from baseline to one month
or from baseline to one year. P2 shows the significance of the difference in change from baseline to
one month or from baseline to one year in the concentration of each biomarker between the ZA and
placebo groups. Significant p-values are in bold.
Serum Biomarkers BaselineMedian (IQR)
1-Month
Median (IQR) P
1 P2
1-Year Median
(IQR) P
1 P2
Bone panel
AFOS (U/L) 0.554 <0.001 *
Placebo 64 (53, 76) 63 (58, 77) 0.480 61 (55, 82) 0.528
ZA 71 (58, 80) 67 (62, 78) 0.826 57 (49, 68) <0.001
RANKL (pg/mL) 0.369 0.724
Placebo 11.3 (0.0, 49.2) 14.6 (0.0, 67.2) 0.470 11.3 (0.0, 59.6) 0.520
ZA 13.0 (0.0, 37.0) 0.0 (0.0, 41.3) 0.891 14.4 (0.0, 48.5) 0.853
iPINP (ng/mL) 0.018 <0.001 *
Placebo 35 (27, 40) 36 (23, 42) 0.729 38 (26, 45) 0.123
ZA 36 (27, 49) 29 (20, 33) 0.004 15 (13, 18) <0.001
CTX-1 (pg/mL) 0.009 0.211
Placebo 0.2 (0.1, 0.4) 0.2 (0.1, 0.6) 0.546 0.3 (0.2, 0.4) 0.189
ZA 0.3 (0.2, 0.5) 0.0 (0.0, 0.0) 0.154 0.2 (0.1, 5.4) 0.927
Chemokine panel
Eotaxin-1 (pg/mL) 0.841 0.398
Placebo 214 (136, 263) 202 (151, 258) 0.956 193 (149, 239) 0.622
ZA 163 (146, 201) 167 (140, 224) 0.841 180 (144, 232) 0.546
Eotaxin-3 (pg/mL) 0.565 0.862
Placebo 17.9 (10.5, 22.7) 16.0 (10.4, 19.6) 0.245 13.9 (11.9, 19.9) 0.261
ZA 20.2 (12.2, 31.6) 18.3 (11.5, 27.6) 0.076 22.3 (12.9, 31.7) 0.388
Diagnostics 2019, 9, 212 6 of 13
Table 2. Cont.
IP-10 (pg/mL) 0.056 0.005 *
Placebo 265 (199, 349) 240 (204, 351) 0.756 248 (171, 305) 0.177
ZA 253 (187, 305) 282 (231, 423) 0.036 316 (240, 420) 0.015
MIP-1A (pg/mL) 0.518 0.817
Placebo 13.5 (5.3, 21.7) 16.7 (5.3, 21.5) 0.818 16.7 (5.3, 19.1) 0.804
ZA 5.3 (5.3, 16.3) 5.3 (5.3, 15.7) 0.945 5.3 (5.3, 17.5) 0.719
MIP-1B (pg/mL) 0.883 0.091
Placebo 126 (79, 156) 102 (91, 161) 0.729 106 (83, 158) 0.177
ZA 85 (58, 144) 87 (63, 136) 0.330 85 (66, 156) 0.277
MCP-1 (pg/mL) 0.327 0.174
Placebo 276 (226, 337) 286 (249, 332) 0.812 267 (222, 346) 0.756
ZA 237 (207, 281) 265 (207, 313) 0.040 279 (206, 326) 0.133
MCP-4 (pg/mL) 0.925 0.429
Placebo 158 (108, 189) 140 (111, 190) 0.674 135 (109, 164) 0.701
ZA 136 (105, 172) 133 (115, 180) 0.571 136 (108, 193) 0.330
MDC-1 (ng/mL) 0.445 0.925
Placebo 1.1 (0.8, 1.4) 1.1 (0.8, 1.4) 0.498 1.1 (0.7, 1.4) 0.546
ZA 1.1 (0.9, 1.3) 1.0 (0.9, 1.2) 0.571 1.0 (0.9, 1.2) 0.701
RANTES (ng/mL) 0.529 0.968
Placebo 78 (48, 168) 85 (52, 116) 0.245 81 (62, 126) 0.261
ZA 72 (50, 163) 80 (41, 126) 0.097 81 (54, 113) 0.648
TARC (pg/mL) 0.157 0.512
Placebo 295 (197, 391) 326 (229, 438) 0.216 329 (198, 411) 0.231
ZA 202 (179, 391) 241 (169, 344) 0.409 269 (161, 383) 0.812
MIG-1 (pg/mL) 0.908 0.122
Placebo 72 (65, 118) 72 (37, 154) 0.880 72 (33, 118) 0.446
ZA 69 (28, 132) 78 (33, 118) 0.939 69 (47, 134) 0.262
Cytokine panel
IL-7 (pg/mL) 0.738 0.445
Placebo 18.0 (14.0, 22.8) 15.8 (11.1, 20.9) 0.452 14.4 (11.4, 17.7) 0.133
ZA 19.3 (15.2, 23.7) 16.2 (13.9, 20.1) 0.154 18.7 (13.9, 21.0) 0.064
IL-12/23p40 (pg/mL) 0.341 0.758
Placebo 122 (92, 157) 113 (87, 185) 0.571 116 (94, 154) 0.898
ZA 102 (77, 145) 97 (84, 134) 0.546 100 (84, 135) >0.999
IL-15 (pg/mL) 0.134 0.678
Placebo 2.8 (2.3, 3.4) 2.6 (2.4, 3.3) 0.985 2.8 (2.5, 3.2) 0.869
ZA 3.0 (2.5, 3.2) 3.1 (2.6, 3.4) 0.123 3.0 (2.7, 3.3) 0.312
IL-16 (pg/mL) 0.301 0.035
Placebo 191 (151, 246) 194 (167, 213) 0.515 172 (156, 200) 0.027
ZA 173 (151, 223) 205 (174, 220) 0.349 207 (167, 248) 0.245
IL-17A (pg/mL) 0.201 0.841
Placebo 2.3 (1.7, 3.3) 2.6 (1.5, 3.3) 0.177 2.6 (1.5, 3.5) 0.869
ZA 2.2 (1.5, 3.3) 2.3 (1.6, 2.9) 0.622 2.2 (1.4, 3.4) 0.829
TNF-B (pg/mL) 0.175 0.636
Placebo 0.4 (0.1, 0.5) 0.4 (0.1, 0.5) 0.761 0.3 (0.1, 0.5) 0.940
ZA 0.1 (0.1, 0.4) 0.1 (0.1, 0.4) 0.240 0.3 (0.1, 0.4) 0.588
Anti-inflammatory panel
IL-1sRII (ng/mL) 0.989 0.391
Placebo 22.1 (18.8, 28.1) 23 (15, 26) 0.515 23 (16, 27) 0.651
ZA 24.7 (20.5, 28.0) 22 (19, 28) 0.522 25 (21, 27) 0.181
Pro-inflammatory panel
IFN-A (pg/mL) 0.329 0.267
Placebo 71 (55, 91) 66 (47, 87) 0.806 66 (55, 95) 0.924
ZA 61 (55, 78) 66 (55, 78) 0.070 71 (58, 79) 0.032
IFN-G (pg/mL) 0.820 0.445
Placebo 5.6 (4.3, 9.3) 4.7 (3.2, 9.6) 0.498 4.6 (3.7, 8.0) 0.245
ZA 4.5 (3.3, 7.1) 5.5 (3.2, 8.8) 0.898 5.3 (3.1, 8.3) 0.756
IL-2R (pg/mL) 0.425 0.625
Placebo 144 (95, 229) 164 (109, 214) 0.225 123 (89, 193) 0.671
ZA 117 (97, 163) 117 (90, 161) 0.588 125 (97, 150) 0.899
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IL-6 (pg/mL) 0.445 0.192
Placebo 0.8 (0.5, 1.1) 0.6 (0.5, 1.1) 0.648 0.7 (0.4, 0.8) 0.105
ZA 0.7 (0.4, 0.9) 0.6 (0.5, 1.0) 0.674 0.6 (0.5, 0.9) 0.522
IL-8 (pg/mL) 0.583 0.659
Placebo 11.1 (7.5, 14.9) 10.2 (7.9, 11.6) 0.040 9.2 (6.8, 12.2) 0.165
ZA 9.7 (7.5, 11.7) 9.7 (7.4, 14.2) 0.294 10.0 (7.6, 13.7) 0.546
TNF-A (pg/mL) 0.512 0.049
Placebo 2.0 (1.6, 2.3) 2.0 (1.7, 2.2) 0.231 1.8 (1.4, 2.2) 0.294
ZA 1.6 (1.2, 2.2) 1.7 (1.3, 2.3) 0.956 1.7 (1.2, 2.5) 0.202
Angiogenesis panel
VEGF-A (pg/mL) 0.758 0.947
Placebo 249 (110, 388) 198 (125, 320) 0.596 182 (111, 406) 0.729
ZA 380 (167, 530) 348 (178, 502) 0.189 412 (170, 497) 0.841
VEGF-C (pg/mL) 0.947 0.369
Placebo 417 (342, 498) 459 (288, 510) 0.812 432 (330, 548) 0.245
ZA 392 (382, 506) 399 (369, 501) 0.596 403 (346, 514) 0.869
VEGF-D (ng/mL) 0.529 0.495
Placebo 0.7 (0.6, 1.0) 0.8 (0.6, 1.0) 0.349 0.8 (0.6, 0.9) 0.105
ZA 0.7 (0.6, 0.9) 0.7 (0.6, 0.8) 0.596 0.7 (0.6, 0.9) 0.571
Tie-2 (ng/mL) 0.529 0.314
Placebo 4.6 (4.0, 5.2) 4.7 (3.7, 5.5) 0.869 4.5 (3.9, 5.1) 0.701
ZA 4.4 (4.0, 5.3) 4.4 (3.7, 5.1) 0.245 4.3 (3.5, 4.9) 0.019
Flt-1 (pg/mL) 0.925 0.989
Placebo 88 (77, 97) 91 (63, 126) 0.812 90 (80, 99) 0.756
ZA 91 (75, 98) 83 (76, 93) 0.349 82 (78, 99) 0.756
bFGF (pg/mL) 0.659 0.659
Placebo 3.4 (1.9, 5.1) 3.2 (2.3, 5.3) 0.869 3.5 (1.9, 8.0) 0.123
ZA 5.2 (2.7, 7.3) 3.7 (2.9, 7.1) 0.522 4.5 (3.8, 8.3) 0.522
HGF-1 (pg/mL) 0.974 0.201
Placebo 205 (110, 263) 184 (115, 248) 0.874 157 (84, 248) 0.245
ZA 146 (89, 219) 143 (67, 193) 0.374 171 (89, 248) 0.430
Vascular injury panel
hs-CRP (mg/L) 0.176 0.551
Placebo 1.2 (0.4, 2.6) 0.9 (0.6, 1.9) 0.936 0.9 (0.6, 2.0) 0.157
ZA 0.9 (0.5, 1.2) 1.3 (0.4, 2.2) 0.042 0.8 (0.4, 1.3) 0.652
ICAM-1 (µg/mL) 0.341 0.773
Placebo 0.4 (0.4, 0.5) 0.4 (0.3, 0.5) 0.368 0.4 (0.3, 0.5) 0.196
ZA 0.4 (0.3, 0.5) 0.4 (0.3, 0.5) 0.622 0.3 (0.3, 0.4) 0.073
VCAM-1 (µg/mL) 0.547 0.603
Placebo 0.6 (0.6, 0.8) 0.6 (0.5, 0.7) 0.409 0.6 (0.5, 0.7) 0.096
ZA 0.6 (0.5, 0.7) 0.5 (0.5, 0.7) 0.841 0.5 (0.5, 0.7) 0.369
SAA (µg/mL) 0.512 0.954
Placebo 1.8 (1.1, 4.1) 1.9 (1.2, 4.2) 0.452 1.7 (1.3, 2.5) 0.595
ZA 1.7 (0.8, 2.2) 1.9 (1.0, 4.3) 0.048 1.5 (0.6, 2.8) 0.922
1 Significance in Wilcoxon signed rank test, 2 Significance in Mann–Whitney’s test; * significant after B–H correction;
AFOS = alkaline phosphatase; bFGF = basic fibroblast growth factor beta; CTX1 = C telopeptide of type I collagen;
Flt = fms related tyrosine kinase (=VEGFR1); HGF = hepatocyte growth factor; hs-CRP = high-sensitive C-reactive
protein; ICAM = intercellular adhesion molecule; IL = interleukin; IFN = interferon; IP = interferon-γ-inducible protein;
iPINP = intact procollagen I N-terminal propeptide; MCP = monocyte chemotactic protein; MDC = macrophage derived
chemokine; MIG = monokine induced by gamma-interferon; MIP = macrophage inflammatory protein; RANKL =
receptor activator of NF-κB ligand; RANTES = regulated upon activation, normally T-expressed, and presumably
secreted; SAA = serum amyloid A; TARC = thymus and activation-regulated chemokine; Tie = TEK receptor tyrosine
kinase; TNF = tumor necrosis factor; VCAM = vascular cell adhesion molecule; VEGF = vascular endothelial
growth factor.
At one-year follow-up, IL-16 in the placebo group, and Tie-2, AFOS and iPINP in the ZA group had
decreased, whereas IP-10 and IFN-A had increased in the ZA group. During the one-year follow-up,
one cytokine biomarker (IL-16) had decreased in the placebo group and two biomarkers (IP-10 and
IFN-A) had increased in the ZA group. The change in IP-10 (decrease of –13.5 in the placebo group vs.
increase of 61.1 pg/mL in the ZA group, p = 0.005) was significant after B–H correction. Two serum
biomarkers (AFOS and iPINP) had not changed in the placebo group but had decreased in the ZA
group (2.5 vs. −9.0 U/l, p < 0.001 and 1.0 vs. −19.1 ng/mL, p < 0.001; respectively). At one year,
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two biomarkers had significantly decreased in the ZA group after B–H correction: AFOS (71 to 57,
p < 0.001) and iPINP (36 to 15, p < 0.001; Table 2).
Among the patients with M2 at baseline, TARC had increased significantly during the one-year
follow-up, whereas among the patients with M1 at baseline, AFOS and iPINP had decreased significantly
(Table S1). In the ZA group, the changes in total volume of MC and M1 volume during the one-year
follow-up correlated positively with the changes in iPINP (Spearman’s correlations (rho) 0.65 and 0.49).
None of the other changes were significant and are presented in Table S2. The changes in LBP intensity
did not correlate statistically significantly with the changes in the concentration of any biomarker,
as shown in Table S3.
4. Discussion
In the present study, a single intravenous infusion of 5 mg ZA gave rise to different trends in the
ZA and placebo groups, leading to significant differences at one-year follow-up in one chemokine
(IP-10), which had increased in the ZA group and decreased in the placebo group, whereas two bone
metabolism biomarkers (AFOS and iPINP) had decreased in the ZA group. Change in iPINP correlated
with the change in the volume of all MC and M1 lesions.
We measured serum levels of AFOS, iPINP, and CTX-1 to evaluate bone formation and resorption.
Of the bone biomarkers, iPINP decreased significantly at both one month and one year and AFOS at one
year in the ZA group. The decreased concentrations in the bone biomarkers were not unexpected, as ZA
has shown to suppress bone remodeling among post-menopausal women with osteoporosis [24,25].
The former [24] documented a 58% reduction in iPINP at one year after ZA administration among
postmenopausal women with osteoporosis, whereas in the present study, iPINP concentration decreased
by 19.4% at one month and 58.3% at one year, compared with 2.8% and 7.9% increases in the placebo
group, respectively. A small French case-control study found no difference in bone mineral density
and bone remodeling marker levels (serum C-terminal crosslinked type 1 telopeptide, procollagen
type 1 N-terminal propeptide, osteocalcin and bone-specific alkaline phosphatase) among chronic LBP
patients with M1 or without MC [20].
In the chemokine panel, IP-10 was elevated at one month and at one year, while MCP-1 was
elevated at one month in the ZA group. Both IP-10 and MCP-1 have been linked to pain [26–29].
In animal models, ZA reduced the expression of a number of pro-inflammatory and angiogenic
mediators, including MCP-1 [30], whereas in our study, MCP-1 was elevated in the ZA group.
In the pro-inflammatory panel, IFN-A was elevated after one year in the ZA group—although
not significantly so after B–H correction. Bisphosphonates do not only inhibit osteoclasts; they have
also shown to suppress the secretion of proinflammatory cytokines such as IL-1, TNF-A, and IL-6 [31].
Several studies have found upregulation of pro-inflammatory cytokines in endplates with MC [32–34]
and local anti-inflammatory treatment with glucocorticoid has shown to have a short-term alleviating
effect on LBP [35]. In our RCT, the improvement in LBP in the ZA group [21] could have been due to
the general ability of bisphosphonates to regulate bone turnover by suppressing osteoclast activity [36]
or to direct anti-inflammatory effects.
In the vascular injury panel, hs-CRP and SAA were elevated after one month in the ZA group
(but not significantly after B–H correction), but at one year there was no difference. Some studies
have shown that administration of bisphosphonates elevates the levels of circulating CRP, IL-6,
TNF-A, and cortisol levels [37,38]. ZA treatment often causes an acute phase reaction with fever
and flu-like symptoms [39]. The published studies of inflammation parameters in MC are based on
tissue samples [32,40,41], but only a few have assessed serum biomarkers. Rannou et al. found that
high-sensitivity C-reactive protein (hsCRP) levels were elevated among patients with M1 and CLBP [19].
An Australian study demonstrated that elevation of CRP and IL-6 during the acute phase of LBP was
associated with better recovery, whereas individuals with elevated TNF had poorer prognoses [42].
It might be that the “window of opportunity” to detect inflammatory serum biomarkers only exists in
the early phase of MC development and shortly after the infusion of bisphosphonates.
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A recent Dutch systematic review found moderate evidence of a positive association between
the pro-inflammatory biomarkers CRP and IL-6 and the severity of nonspecific LBP, and a positive
association between TNF-A and the presence of nonspecific LBP [43]. If it were possible to determine a
fingerprint in the serum of patients with LBP that is associated with MC, serum profiling could be
used to assess the prognosis and choice of treatment. Khan et al. [44] emphasized the potential of
diagnostic biomarkers to guide an era of individualized spine medicine for personalized therapeutics
in the treatment of LBP. In our study, however, the changes in LBP intensity did not correlate with the
changes in any biomarker’s concentration.
Because of their potent antiresorptive activity, bisphosphonates, including ZA, represent standards
of care for the treatment of osteoporosis. Studies in vitro and in vivo have shown that, for example,
pamidronate and clodronate inhibit the synthesis of proinflammatory cytokines [45,46]. It has been
proposed that the development of MC is dependent on the structural disruption of the intervertebral
disc or endplate, and the inflammatory potential of the disc and the capacity of the bone marrow
to respond to higher inflammatory stimuli [13]. The source of pain is probably the chemical and
mechanical stimulation of the nociceptors adjacent to the damaged endplates. It has also been
suggested that a low virulent infection of anaerobic bacteria may induce edema and inflammation [47].
When we exclude the theory of anaerobic infection from the pathophysiology of MC, we notice that
ZA has several potential mechanisms for acting in MC lesions and is a promising, well-known and
well-tolerated drug for treating LBP associated with MC. In the present study we could not prove the
downregulation of serum biomarkers, including cytokines and growth factors, after ZA administration
among LBP patients with MC. This might be due to our small sample size.
The strength of the present study is its randomized study design. Further strengths are its complete
follow-up with no dropouts and 100% adherence, as medication was administered intravenously.
All the analyses were performed using established, validated measurement assays in high-quality
laboratories. Longitudinal data enable a better view of the possible inflammatory component in LBP
with MC. However, we also acknowledge some limitations in our study. The small sample size of
this pilot study might be inadequate to demonstrate significant changes in biomarkers, and multiple
testing might increase the rate of false positive results. Thus, our results should be interpreted with
caution. The possible presence of comorbidities and adverse lifestyles may affect the proinflammatory
mediators observed in the systemic circulation of patients. For example, obesity is associated with
increased serum levels of IL-6 and TNF-A [48], and smoking is characterized by elevated serum levels
of, for example, TNF-A and IL-1, as well as other cytokines [49].
5. Conclusions
The present data demonstrated that a single intravenous infusion of 5 mg ZA gave rise to different
trends in serum biomarkers in the ZA and placebo groups, leading to significantly different regulations
at one-year follow-up for one chemokine (IP-10), whereas two bone metabolism biomarkers (AFOS
and iPINP) decreased in the ZA group. ZA treatment had an expected downregulating effect on bone
turnover markers. This study found an association, a positive correlation, between a change in iPINP
concentration and the change in total volume of MC and M1 volume. The changes in LBP intensity did
not correlate with the changes in any biomarker’s concentration.
This is the first RCT to investigate ZA in MC and to observe how it is reflected in serum biomarkers.
The evaluation of these biomarkers expands our understanding of the mechanism of MC and LBP and
may thereby guide us to new diagnostic and therapeutic methods. It adds to our knowledge of the
effects of ZA on MC and on the biomarkers signaling this process. We conclude that serum biomarkers
can be used to monitor the treatment effect of ZA among LBP patients with MC. Larger studies are
required to demonstrate the findings of this pilot study.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/link.
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Abbreviations
AFOS alkaline phosphatase
bFGF fibroblast growth factor beta
COMP cartilage oligomeric matrix protein
CTX1 C telopeptide of type I collagen
Flt fms related tyrosine kinase (=VEGFR1)
hs-CRP high-sensitive C-reactive protein
HGF hepatocyte growth factor
ICAM intercellular adhesion molecule
IL interleukin
IFN interferon
IP interferon-γ-inducible protein
iPINP intact procollagen I N-terminal propeptide
LBP low back pain
MC Modic change
M1 type 1 Modic change
M2 type 2 Modic change
MCP monocyte chemotactic protein
MDC, macrophage derived chemokine
MIG monokine induced by gamma-interferon
MIP macrophage inflammatory protein
MRI magnetic resonance imaging
ODI Oswestry Disability Index
RANKL receptor activator of NF-κB ligand
RANTES regulated upon activation, normally T-expressed, and presumably secreted
SAA serum amyloid A
SD standard deviation
TARC thymus and activation-regulated chemokine
Tie TEK receptor tyrosine kinase
TNF tumor necrosis factor
VAS Visual Analog Scale
VCAM vascular cell adhesion molecule
VEGF vascular endothelial growth factor
ZA zoledronic acid
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